- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02050243
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors (5-ALA)
The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors
Surgery is the cornerstone treatment of most pediatric CNS tumors, including astrocytomas, ependymomas, medulloblastomas, and many other pathologies.
In most pediatric CNS tumors, the aim of surgery is maximal tumor resection, while preserving neurological function. Extent of tumor residual has been shown to be a major prognostic factor for progression free survival (PFS), and survival in several malignant and low-grade tumors such as medulloblastomas, ependymomas, and astrocytic tumors.
5-aminolevulinic acid (5-ALA) has been shown to be valuable in intraoperative marking of various cancers. Following oral admission, during surgery, the tumor tissue is illuminated by blue light. Tumor cells tend to metabolize 5-ALA to a porphyrin named protoporhyrin IX (PpIX). PpIX reacts with the blue light and emits a pinky color (- fluorescence). This enables the surgeon to better identify tumor cells and perform a more extensive resection.
Over recent years, many studies have proven the efficacy using 5-ALA for resecting various intracranial and spinal tumors, thus achieving a better tumor control.
In the suggested study, we propose using the same technique for various pediatric central nervous system tumors.
We will focus on the correlation between various pathologies and the fluorescence, trying to deduce the role of 5-ALA in resection of specific pathologies.
Also, we will study the safety of 5-ALA use in the pediatric population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Following the above general description, eligible children will receive 5-aminolevulinic acid (5ALA) prior to surgery.
During surgery, careful attention will be payed to the fluorescence from the tumor, as well as the ability to differentiate between tumor and non tumorous tissue.
Comparisons between fluorescence and pathologies will be performed. Additionally, careful documentation of side effects will be done, to increase the safety of 5ALA use.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Jonathan Roth, MD
- Phone Number: 972-524262095
- Email: jonaroth@gmail.com
Study Locations
-
-
-
Tel-Aviv, Israel, 64239
- Department of pediatric neurosurgery
-
Contact:
- Jonathan Roth, MD
- Phone Number: 972-524262095
- Email: jonaroth@gmail.com
-
Principal Investigator:
- Jonathan Roth, MD
-
Sub-Investigator:
- Shlomi Constantini, MD, MSc
-
Sub-Investigator:
- Liana Beni-Adani, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 3 -18 years old
- Any CNS related pathology (including intraaxial and extraaxial tumors, intracranial or spinal intradural) that is planned for either open (microscopic) resection (or biopsy), or lesions undergoing stereotactic biopsies.
- Parental consent
- No personal or familial (1st degree) history of porphyria
- Liver function test within normal limits (alanine aminotransferase (ALT), aspartate aminotransferase (AST)<2 * upper normal limit)
- Normal renal function (Cr <2)
Exclusion Criteria:
- Surgery with no microscopic use (i.e. purely endoscopic surgeries)
- History of hepatic disease within last 12 months
- History of cutaneous photosensitivity, hypersensitivity to porphyrins, photodermatosis, exfoliative dermatitis, or porphyria
- Inability to comply with photosensitivity precautions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 5ALA
All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
|
20mg/kg of oral suspension of 5ALA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sensitivity of 5ALA fluorescence to intraoperatively detect pediatric CNS tumor tissue
Time Frame: up to 2 weeks
|
about 3hour following the 5ALA admission, the patient undergoes surgery.
during surgery, global impression of tumor fluorescence will be appreciated (none, inhomogenous, intense homogenous) additionally, tumor samples will be taken from various regions, including various fluorescence regions, to try and correlate tumor regions (e.g.
necrosis and viable tumor) with fluorescence (and measure the sensitivity of the 5ALA to the specific tumor)
|
up to 2 weeks
|
number of patients with 5ALA related side effects
Time Frame: 2 weeks
|
5ALA is known to cause skin hypersensitivity reaction following direct sun light exposure, during the first 48 hours after admission. also, transient elevation in liver enzymes have been documented. the investigators will supervise these reactions during the postoperative phase |
2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TASMC-13-JR-528-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Tumor, Pediatric
-
Memorial Sloan Kettering Cancer CenterColumbia University; University of Washington; University of Texas; Rutgers UniversityActive, not recruitingBrain Tumor | Pediatric Cancer | Pediatric Brain TumorUnited States
-
University of Alabama at BirminghamTerminated
-
University of California, San FranciscoCompletedPediatric Brain TumorsUnited States
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Sabine Mueller, MD, PhDWashington University School of Medicine; Nationwide Children's Hospital; Rally...Not yet recruitingPediatric Brain Tumor | Recurrent Pediatric Brain Tumor | Pediatric Supratentorial NeoplasmUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...CNOG-MC001 Collaborative GroupCompletedPediatric Brain Tumor | Malignant Brain Tumor | Tumors, Central Nervous System | Benign Brain TumorChina
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingCentral Nervous System Tumor | Somatic Mutation | Pediatric Central Nervous System Tumor | Discordant TwinUnited States
-
Westfälische Wilhelms-Universität Münsterphotonamic GmbH & Co. KG; medac GmbHRecruitingBrain Tumor, PediatricGermany, Netherlands
-
Sheffield Children's NHS Foundation TrustGE Healthcare; University of SheffieldNot yet recruitingBrain Tumor, Pediatric
-
Washington University School of MedicineNot yet recruitingBrain Tumor, PrimaryUnited States
Clinical Trials on 5ALA
-
Northwell HealthOlympus CorporationRecruitingMalignant Glioma of BrainUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingNon-muscle-invasive Bladder CancerChina